Boehringer Ingelheim and Yuhan Corp. have entered a collaboration and license agreement to develop a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. Yuhan will provide its expertise in FGF21 biology, obesity and NASH. NASH often starts with the accumulation of fat in the liver, giving rise to inflammation and finally leading in many patients to liver fibrosis and cirrhosis. It has an especially high preva...